Actively Recruiting

Age: 18Years +
All Genders
ID06923449

Gastric Cancer Textbook Oncological Outcome and Tumor Board Performance at a High-Volume Italian University Hospital

Led by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Updated on 2025-04-11

250

Participants Needed

1

Research Sites

8 weeks

Total Duration

On this page

Sponsors

F

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Lead Sponsor

S

Società Italiana di Chirurgia Oncologica SICO - ESSO affiliated

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are evaluating the outcomes of patients with gastric cancer who undergo surgery with curative intent before and after the creation of a Multidisciplinary Tumor Board (MTB) at Fondazione Policlinico Gemelli. This observational study compares surgical and oncologic results, focusing on whether the MTB has improved the quality of care and patient outcomes by reviewing cases weekly in a team setting. The study covers patients treated from January 2018 to the present, with the MTB established in November 2019. The study groups include patients treated before the MTB was established (January 2018 to November 2019) and those treated afterward (December 2019 onward). Data collection involves reviewing clinical, pathological, surgical, and oncological information for patients with gastric adenocarcinoma who are surgical candidates with curative intent. The MTB's influence on treatment allocation, timing from diagnosis to treatment, and overall adherence to tumor board recommendations is assessed. Participants' medical records will be analyzed for outcomes such as Textbook Outcome (TO), Textbook Oncological Outcome (TOO), time from diagnosis to first treatment (TTT), patient-to-treatment allocation (PTA), and tumor board adherence (TBA). These measures help evaluate the effectiveness of the MTB in improving patient care. The study collects data retrospectively up to February 2024, aiming to detect improvements in surgical and oncological results over time.

CONDITIONS

Brief Title

Gastric Cancer' Textbook Oncological Outcome and Tumor Board Performance

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Pathology-confirmed diagnosis of gastric adenocarcinoma
  • Age 18 years or older
  • Surgical candidates with curative intent
Not Eligible

You will not qualify if you...

  • Endoscopic Mucosal Resection (EMR) or Endoscopic Submucosal Dissection (ESD)
  • Previous EMR or ESD (salvage surgery)
  • Histologies other than adenocarcinoma (no squamous cell carcinomas, GISTs, sarcomas, lymphomas, etc)
  • Insufficient staging (unclear clinical stage at diagnosis)
  • Emergency presentation (obstructed, significantly bleeding, perforated gastric cancer)
  • Synchronous tumors affecting survival
  • Pregnant patients
  • Age under 18 years

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Monitoring

Duration - From January 2018 to February 2024

Participants who undergo routine care for gastric cancer are observed to assess the impact of the Multidisciplinary Tumor Board on treatment outcomes and performance indicators.

Visits occur as part of routine clinical care

Trial Site Locations

Total: 1 location

1

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Rome, IT, Italy, 00168

Actively Recruiting

Loading map...

Research Team

L

Laura Antolino, MD, PhD

C

Cristina Vacca

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Similar Trials

[18F]F-FAPI PET/CT and Laparoscopy in Staging Advanced Gastr...

Locally Advanced Gastric Adenocarcinoma

Actively Recruiting

10 locations

A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, and S...

Stomach Neoplasm

Actively Recruiting

1 location

A Phase Ib/II Trial of Neoadjuvant Zolbetuximab Plus Docetax...

Stomach Neoplasm

Actively Recruiting

2 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Published Research Related To This Trial

Union is strength: Textbook outcome with perioperative chemotherapy compliance decreases the risk of death in advanced gastric cancer patients.

Katarzyna Sędłak, Karol Rawicz-Pruszyński, Radosław Mlak...

https://pubmed.ncbi.nlm.nih.gov/34404560

The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: A systematic review of the literature.

Brindha Pillay, Addie C Wootten, Helen Crowe...

https://pubmed.ncbi.nlm.nih.gov/26643552

The comprehensive complication index (CCI) is a more sensitive complication index than the conventional Clavien-Dindo classification in radical gastric cancer surgery.

Tae-Han Kim, Yun-Suhk Suh, Yeon-Ju Huh...

https://pubmed.ncbi.nlm.nih.gov/28597328